Back to top

Analyst Blog

Novartis (NVS - Snapshot Report) recently received encouraging news when its meningococcal serogroup B vaccine B (MenB) vaccine, Bexsero, was approved in Australia, for use in age groups of two months and above.

We note that Bexsero was approved in the EU earlier this year for use in children over two months old.

As per Novartis, meningococcal disease causes approximately 50,000 deaths on an annual basis due to infection from five serogroups—A, B, C, W-135 and Y.  

Novartis’ meningococcal franchise consists of three vaccines – Bexsero, Menjugate and Menveo. We are encouraged by the recent pipeline progress at Novartis with both Bexsero and Menveo.

Earlier in the month, the U.S. Food and Drug Administration (FDA) approved the label expansion of Menveo thereby allowing the use of the vaccine for protection against meningococcal disease in infants and toddlers aged 2 months and above.

With the label expansion, Menveo can now be used in infants, children and adolescents.

Other meningococcal vaccines under development include MenABCWY (serogroups A, B, C, Y and W-135), which is currently in phase III.

We believe the label expansion of Menveo and approval of Bexsero in early 2013 will strengthen Novartis' meningococcal franchise and boost results going forward.

In 2012, Novartis’ Vaccines and Diagnostics Division generated net sales of $1.9 billion, down 7% year over year.

Influenza vaccines are the core products of this division, which includes brands such as Fluvirin, Fluad, Agrippal, Optaflu and Flucelvax.

Novartis expects to file for the label expansion of Fluad for use in adults aged 65 years and above later in 2013 and initiate a phase III study on Quadrivalent Influenza Vaccine.

Sanofi’s (SNY - Analyst Report) Menactra is indicated to treat meningococcal meningitis. Meanwhile, GlaxoSmithKline’s (GSK - Analyst Report) Menhribrix is approved for prevention of invasive disease caused by Neisseria meningitidis serogroups C and Yand Haemophilus influenzae type b.

Novartis currently carries a Zacks Rank #4 (Sell).  Right now, Biogen Idec Inc. (BIIB - Analyst Report) looks attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%